Angiokinase Inhibition and Nintedanib (BIBF 1120)*

Boehringer Ingelheim

Nintedanib (BIBF 1120*), a Boehringer Ingelheim investigational compound, is an oral triple angiokinase inhibitor which simultaneously blocks three angiogenesis signalling pathways and therefore affects tumour growth.

How does angiogenesis work?¹
Angiogenesis is a normal function in the body that helps new blood vessels grow. It is necessary for wound healing, reproduction and embryo development. Angiogenesis is mediated through growth factors (VEGF, FGF and PDGF).

When blocking only one angiokinase...
...tumours can become resistant to VEGFR inhibition and use alternative signalling pathways, such as FGFR, to sustain growth.

How does nintedanib^* work?²
Clinical trials showed that nintedanib* acts on all three receptors – FGFR, VEGFR and PDGFR, thereby inhibiting all signalling pathways involved in angiogenesis. This tumour stabilisation or shrinkage due to lack of oxygen and nutrients

*Nintedanib (BIBF 1120) is an investigational compound. Its safety and efficacy has not yet been fully established.

1. Ellis, L.M. and Hicklin, D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 2008;8: 579-59.

2. Hilberg F et al. BIBF1120: Triple angiokinase inhibitor with sustained receptor blockade and good anti-tumor efficacy. Cancer Research 2008;68(12): 4774-4782.

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on